A Phase 2 Study of CIM331 for Atopic Dermatitis Patients
Status:
Completed
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
To assess the safety, tolerability and efficacy of CIM331, compared to placebo, in atopic
dermatitis patients who are inadequately controlled by or intolerant to topical therapy